Literature DB >> 9731044

Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor.

H P Kiem1, R G Andrews, J Morris, L Peterson, S Heyward, J M Allen, J E Rasko, J Potter, A D Miller.   

Abstract

We have used a competitive repopulation assay in baboons to develop improved methods for hematopoietic stem cell transduction and have previously shown increased gene transfer into baboon marrow repopulating cells using a gibbon ape leukemia virus (GALV)-pseudotype retroviral vector (Kiem et al, Blood 90:4638, 1997). In this study using GALV-pseudotype vectors, we examined additional variables that have been reported to increase gene transfer into hematopoietic progenitor cells in culture for their ability to increase gene transfer into baboon hematopoietic repopulating cells. Baboon marrow was harvested after in vivo administration (priming) of stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF). CD34-enriched marrow cells were divided into two equal fractions to directly compare transduction efficiencies under different gene transfer conditions. Transduction by either incubation with retroviral vectors on CH-296-coated flasks or by cocultivation on vector-producing cells was studied in five animals; in one animal, transduction on CH-296 was compared with transduction on bovine serum albumin (BSA)-coated flasks. The highest level of gene transfer was obtained after 24 hours of prestimulation followed by 48 hours of incubation on CH-296 in vector-containing medium in the presence of multiple hematopoietic growth factors (interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor). Using these conditions, up to 20% of peripheral blood and marrow cells contained vector sequences for more than 20 weeks, as determined by both polymerase chain reaction and Southern blot analysis. Gene transfer rates were higher for cells transduced on CH-296 as compared with BSA or cocultivation. In one animal, we have used a vector expressing a cell surface protein (human placental alkaline phosphatase) and have detected 10% and 5% of peripheral blood cells expressing the transduced gene 2 and 4 weeks after transplantation as measured by flow cytometry. In conclusion, the conditions described here have resulted in gene transfer rates that will allow detection of transduced cells by flow cytometry to facilitate the evaluation of gene expression. The levels of gene transfer obtained with these conditions suggest the potential for therapeutic efficacy in diseases affecting the hematopoietic system. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731044

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 2.  Gene therapy for the hemoglobin disorders: past, present, and future.

Authors:  D A Persons; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors.

Authors:  S S Case; M A Price; C T Jordan; X J Yu; L Wang; G Bauer; D L Haas; D Xu; R Stripecke; L Naldini; D B Kohn; G M Crooks
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro.

Authors:  I Hamaguchi; N B Woods; I Panagopoulos; E Andersson; H Mikkola; C Fahlman; R Zufferey; L Carlsson; D Trono; S Karlsson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 5.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

6.  Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

Authors:  Alice F Tarantal; Francesca Giannoni; C Chang I Lee; Jennifer Wherley; Teiko Sumiyoshi; Michele Martinez; Christoph A Kahl; David Elashoff; Stan G Louie; Donald B Kohn
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

Review 7.  Hematopoietic-stem-cell-based gene therapy for HIV disease.

Authors:  Hans-Peter Kiem; Keith R Jerome; Steven G Deeks; Joseph M McCune
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

8.  Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector.

Authors:  S E Suter; T A Gouthro; P A McSweeney; R A Nash; M E Haskins; P J Felsburg; P S Henthorn
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

9.  Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin.

Authors:  Pedro Lei; Bharat Bajaj; Stelios T Andreadis
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  Retroviral vector interactions with hematopoietic cells.

Authors:  Elizabeth M Everson; Grant D Trobridge
Journal:  Curr Opin Virol       Date:  2016-08-10       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.